Universitat de Barcelona-ko ikertzaileekin lankidetzan egindako argitalpenak (18)

2023

  1. A new FGF15/19-mediated gut-to-heart axis controls cardiac hypertrophy

    Journal of Pathology, Vol. 261, Núm. 3, pp. 335-348

  2. Author Correction: Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis (Nature Communications, (2019), 10, 1, (3126), 10.1038/s41467-019-11004-3)

    Nature Communications

  3. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma

    Journal of Hepatology, Vol. 79, Núm. 4, pp. 989-1005

  4. The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent

    Hepatology (Baltimore, Md.), Vol. 78, Núm. 3, pp. 878-895

2022

  1. Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions

    Gut, Vol. 71, Núm. 8, pp. 1669-1683

  2. DNA Methylation Regulates a Set of Long Non-Coding RNAs Compromising Hepatic Identity during Hepatocarcinogenesis

    Cancers, Vol. 14, Núm. 9

2021

  1. Armcx3 mediates susceptibility to hepatic tumorigenesis promoted by dietary lipotoxicity

    Cancers, Vol. 13, Núm. 5, pp. 1-22

  2. Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH

    Medicina Clinica, Vol. 156, Núm. 9, pp. 463.e1-463.e30

  3. FGF15/19 is required for adipose tissue plasticity in response to thermogenic adaptations

    Molecular Metabolism, Vol. 43

  4. The tgf-β pathway: A pharmacological target in hepatocellular carcinoma?

    Cancers, Vol. 13, Núm. 13

2019

  1. Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis

    Nature Communications, Vol. 10, Núm. 1

2018

  1. Gut roundtable meeting paper: Selected recent advances in hepatocellular carcinoma

    Gut, Vol. 67, Núm. 2, pp. 380-388

2017

  1. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies

    Nature Communications, Vol. 8

  2. Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatosis: Development of an FGF19-based chimeric molecule to promote fatty liver regeneration

    Gut, Vol. 66, Núm. 10, pp. 1818-1828

  3. The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells

    Hepatology, Vol. 65, Núm. 6, pp. 2031-2044

2016

  1. Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats

    Journal of Hepatology, Vol. 64, Núm. 4, pp. 834-842

2003

  1. Methionine adenosyltransferase II β subunit gene expression provides a proliferative advantage in human hepatoma

    Gastroenterology, Vol. 124, Núm. 4, pp. 940-948

2000

  1. Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma

    Journal of Hepatology, Vol. 33, Núm. 6, pp. 907-914